12.07.2023
SP848
An open-label study to determine safety, tolerability, and efficacy of long-term oral Lacosamide (lcm) as adjunctive therapy in children with epilepsy
Show more12.07.2023
20150125 OASIS PEDIATRIC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]) < < [EM]
Show more12.07.2023
20160354 OASIS PEDIATRIC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM]) < < [CM]
Show more12.07.2023
109MS306 CONNECT
Open-Label, Randomized, Multicenter, Multiple-Dose, Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension
Show more12.07.2023
ECU-NMO-303
A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients with Relapsing Neuromyelitis Optica Spectrum Disorder
Show more12.07.2023
H8H-MC-LAHW PIONEER-PEDS2
Protocol H8H-MC-LAHW A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine – PIONEER-PEDS2
Show more12.07.2023
H8H-MC-LAHV PIONEER-PEDS1
Protocol H8H-MC-LAHV(a) Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Show more12.07.2023
WA39085 Operetta 1
An open-label, parallel-group study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamic effects of Ocrelizumab in children and adolescents with relapsing-remitting multiple sclerosis
Show more12.07.2023
1042-0900
A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children with PCDH19 Female Pediatric Epilepsy
Show more